Breaking News

Lonza Completes Divestment of Sites to NextPharma

Lonza exits both softgels and liquid-filled hard capsules and NextPharma plans to broaden its technology offering into lipid based finished dosage forms.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lonza completed the divestment of its Ploermel, France and Edinburgh, UK sites to NextPharma, exiting both softgels and liquid-filled hard capsules for the pharma market but retaining capability for feasibility studies as part of a technology selection offering. The Ploermel and Edinburgh sites employ around 260 and 130 permanent staff respectively. They produce liquid-filled hard capsules, including Licaps, and softgels for high potent and hormonal products.   NextPharma offers specialized...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters